174 related articles for article (PubMed ID: 37190167)
1. STAT3 Inhibition Attenuates MYC Expression by Modulating Co-Activator Recruitment and Suppresses Medulloblastoma Tumor Growth by Augmenting Cisplatin Efficacy In Vivo.
Rohrer KA; Song H; Akbar A; Chen Y; Pramanik S; Wilder PJ; McIntyre EM; Chaturvedi NK; Bhakat KK; Rizzino A; Coulter DW; Ray S
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190167
[TBL] [Abstract][Full Text] [Related]
2. Suppression of STAT3 NH
Ray S; Coulter DW; Gray SD; Sughroue JA; Roychoudhury S; McIntyre EM; Chaturvedi NK; Bhakat KK; Joshi SS; McGuire TR; Sharp JG
Mol Carcinog; 2018 Apr; 57(4):536-548. PubMed ID: 29280516
[TBL] [Abstract][Full Text] [Related]
3. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
4. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
[TBL] [Abstract][Full Text] [Related]
6. Targeting the gp130/STAT3 Axis Attenuates Tumor Microenvironment Mediated Chemoresistance in Group 3 Medulloblastoma Cells.
Sreenivasan L; Li LV; Leclair P; Lim CJ
Cells; 2022 Jan; 11(3):. PubMed ID: 35159191
[TBL] [Abstract][Full Text] [Related]
7. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
[TBL] [Abstract][Full Text] [Related]
8. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
Marquardt V; Theruvath J; Pauck D; Picard D; Qin N; Blümel L; Maue M; Bartl J; Ahmadov U; Langini M; Meyer FD; Cole A; Cruz-Cruz J; Graef CM; Wölfl M; Milde T; Witt O; Erdreich-Epstein A; Leprivier G; Kahlert U; Stefanski A; Stühler K; Keir ST; Bigner DD; Hauer J; Beez T; Knobbe-Thomsen CB; Fischer U; Felsberg J; Hansen FK; Vibhakar R; Venkatraman S; Cheshier SH; Reifenberger G; Borkhardt A; Kurz T; Remke M; Mitra S
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639156
[TBL] [Abstract][Full Text] [Related]
9. Histone chaperone FACT complex inhibitor CBL0137 interferes with DNA damage repair and enhances sensitivity of medulloblastoma to chemotherapy and radiation.
Song H; Xi S; Chen Y; Pramanik S; Zeng J; Roychoudhury S; Harris H; Akbar A; Elhag SS; Coulter DW; Ray S; Bhakat KK
Cancer Lett; 2021 Nov; 520():201-212. PubMed ID: 34271103
[TBL] [Abstract][Full Text] [Related]
10. Frondoside A Inhibits an MYC-Driven Medulloblastoma Model Derived from Human-Induced Pluripotent Stem Cells.
Xue Y; Fu Y; Zhao F; Gui G; Li Y; Rivero-Hinojosa S; Liu G; Li Y; Xia S; Eberhart CG; Ying M
Mol Cancer Ther; 2021 Jun; 20(6):1199-1209. PubMed ID: 33722850
[TBL] [Abstract][Full Text] [Related]
11. RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells.
von Bueren AO; Shalaby T; Oehler-Jänne C; Arnold L; Stearns D; Eberhart CG; Arcaro A; Pruschy M; Grotzer MA
BMC Cancer; 2009 Jan; 9():10. PubMed ID: 19134217
[TBL] [Abstract][Full Text] [Related]
12. Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling.
Nazio F; Po A; Abballe L; Ballabio C; Diomedi Camassei F; Bordi M; Camera A; Caruso S; Caruana I; Pezzullo M; Ferraina C; Milletti G; Gianesello M; Reddel S; De Luca CD; Ceglie D; Marinelli S; Campello S; Papaleo E; Miele E; Cacchione A; Carai A; Vinci M; Velardi E; De Angelis B; Tiberi L; Quintarelli C; Mastronuzzi A; Ferretti E; Locatelli F; Cecconi F
Acta Neuropathol; 2021 Sep; 142(3):537-564. PubMed ID: 34302498
[TBL] [Abstract][Full Text] [Related]
13. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.
Bouillez A; Rajabi H; Pitroda S; Jin C; Alam M; Kharbanda A; Tagde A; Wong KK; Kufe D
Cancer Res; 2016 Mar; 76(6):1538-48. PubMed ID: 26833129
[TBL] [Abstract][Full Text] [Related]
15. Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy.
Chaturvedi NK; Kling MJ; Coulter DW; McGuire TR; Ray S; Kesherwani V; Joshi SS; Sharp JG
Oncotarget; 2018 Mar; 9(24):16619-16633. PubMed ID: 29682173
[TBL] [Abstract][Full Text] [Related]
16. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
17. Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
Han Y; Lindner S; Bei Y; Garcia HD; Timme N; Althoff K; Odersky A; Schramm A; Lissat A; Künkele A; Deubzer HE; Eggert A; Schulte JH; Henssen AG
Cancer Lett; 2019 Mar; 445():24-33. PubMed ID: 30611741
[TBL] [Abstract][Full Text] [Related]
18. Effective Inhibition of
Zhao Y; Li T; Tian S; Meng W; Sui Y; Yang J; Wang B; Liang Z; Zhao H; Han Y; Tang Y; Zhang L; Ma J
Cancer Manag Res; 2020; 12():12473-12485. PubMed ID: 33299354
[TBL] [Abstract][Full Text] [Related]
19. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
20. Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma.
Chan TSY; Picard D; Hawkins CE; Lu M; Pfister S; Korshunov A; Roussel MF; Wechsler-Reya RJ; Henkin J; Bouffet E; Huang A
Neurooncol Adv; 2021; 3(1):vdab002. PubMed ID: 33629064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]